Hope for reducing SA's trauma deaths? by Bateman, Chris
A so-called ‘blood substitute’ that can
give physicians up to 19 hours of respite
in time-critical blood transfusions is
being used for the first time in a clinical
setting for acute trauma patients,
making South Africa the only country in
the world to do so. 
If the trial proves successful and
increased production lowers costs, the
drug could help South Africa shrug off
the unwelcome mantle of being a world
leader in all-cause trauma mortality.
The product is licensed for exclusive
use in acute anaemia. Called Hemopure,
it improves oxygen transportation
without toxicity dangers, but is still far
from being a blood substitute – one of
the ultimate goals of its developers. 
The theory is that it might be better
than blood for perfusing certain hypo-
perfusion states like shock and that it
will improve oxygen levels in the tissues
after a surgical procedure. However, this
is as yet unproven and in the
Johannesburg Hospital the most far-
reaching trial is about to begin – testing
its use in clinical trauma situations.
Says Dr Charl van Loggerenberg,
General Manager of Biopure South
Africa: ‘If this type of study helps bring
an oxygen-carrying fluid closer to the
point of need then it is has the potential
to save many lives.’
The Medicines Control Council has so
far only registered it (in 2001) for
treating adult surgical patients who are
acutely anaemic and for delaying the
need for a predictable blood transfusion
in these patients. 
Principal investigator for the local leg
of the multinational trials, Professor Ken
Boffard, head of surgery at
Johannesburg General Hospital,
described Hemopure as a haemoglobin-
based oxygen carrier (HBOC) or an
‘oxygen bridge’ between cell and tissue. 
Hemopure (created using
haemoglobin polymer synthesised from
bovine haemoglobin) and another
similar product, Polyheme (derived from
human haemoglobin), has been under
evaluation in the trauma setting for
about a year, with the latter in trial use
by paramedics in non-hospital settings
in Denver, Colorado. Both drugs are
fully accepted by Jehovah’s Witnesses,
who have long prompted ethical
controversy by refusing potentially life-
saving blood transfusions. The drugs
have been in veterinary use for about 5
years.
Boffard and his colleagues, who are
working intimately with the Federal
Drug Administration (FDA) and the
local Medicines Control Council (MCC),
secured the ethics go-ahead for the
trauma trial in February this year after a
strict 5-month vetting process.
They will use 50 volunteers, each of
whom requires some 40 hours of
assessment over and above normal
medical care. Other clinicians associated
with the team will set up an ‘absolutely
consistent’ laboratory.
Boffard expects to see the first results
in about a year when he sits down with
the statisticians, independent assessors
and the MCC. He says local vascular
surgeons are already using Hemopure
extensively. Its chief known benefits
include being stable at room
temperature, having a shelf life of 3
years, being easy to store and
eliminating blood cross-matching
problems.
He cautioned surgeons to take
haemoglobin measurements from
patients before administering
Hemopure, saying machine readings
could otherwise be difficult to interpret.
Van Loggerenberg says his company
trains all hospital laboratory staff before
the product is introduced but agreed
that were this not the case, ‘you could
have a problem result’.
Both men dismiss ‘Mad Cow’ or any
other disease being potentially
transmissible, emphasising that it is a
synthetic product using haemoglobin
chains derived from bovine
haemoglobin. All possible infectious
diseases are ‘eradicated in the
manufacturing process’.
‘It’s so far removed from the original
haemoglobin that it’s safe to call it a
synthetic product – which is why the
Jehovah’s Witnesses allow it,’ said van
Loggerenberg.
The product drew controversy when
described as ‘cow’s blood’ in the lay
media in Johannesburg, alarming several
people potentially enrolled into the trials
who had yet to go through the strict
informed educational consent process.
Boffard emphasised that Hemopure
was ‘not a substitute for anything else
we do. All the patients get normal
treatment but half of them get this as
well at no extra cost’. Both men
confirmed that the reportage in the
Citizen newspaper had resulted in a
worried call from the national
Department of Health. The DOH was
reassured that no unauthorised
‘experimentation’ was underway.
Dr Robert Crookes, medical director of
the South African National Blood
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Service (SANBS), says that while a
potential life-saver, Hemopure does not,
in the vast majority of patients, replace
the need for red cells, platelets or
clotting factors that were found in fresh
frozen plasma. It would not impact on
the country’s current blood needs nor
was it a viable routine alternative to
blood.
‘Its risks and side-effects have to be
carefully evaluated and then compared
with those of ordinary blood – it’s no
use substituting an alternative therapy
for one that might have an increased
risk,’ he adds. Crookes says that the
SANBS has put in place highly effective
measures to manage the risk of
transfusion-transmissible diseases via
blood.
Van Loggerenberg and Boffard agreed,
adding that South Africa had an
enviable reputation for safe blood in
spite of a 26% HIV prevalence in the
general population. ‘We have some of
the safest blood in the world – it’s far
more aggressively screened than most
other places and it’s a superb service,’
adds Boffard.
Asked how long it would be before an
artificial blood product became a reality,
he said he believed this would come
within 5 years.
Crookes says the reported HIV
incidence in the SANBS’s latest annual
haemo-vigilance report is one in 390 000
transfusions. The actual calculated risk
(taking into account the window period
of HIV infection and the HIV
seroprevalence of donors) is currently
approximately one in 100 000. There
were five HIV transfusion
‘breakthroughs’ in the over 4 million
blood products transfused in the past 5
years (881 000 transfusions last year).
Dr Theresa Nel, a lead consultant with
the SANBS, told the SAMJ that 66% of
all transfusion reactions are the result of
the patient receiving the wrong unit of
blood and the ensuing reactions are
mainly attributable to human error. A
full 59% of these occurred at the
bedside. Last year just three ‘probable
cases’ of disease transmission by blood
transfusion were reported, one a
bacterial infection and the other two
HIV window period transmissions.
‘What happens is people don’t declare
high-risk behaviour  – we’ve learnt that
more stringent donor education is
needed to secure self-exclusion. It’s
difficult because they don’t think they’ve
been risky.’
Nel said she saw the current
application of Hemopure as being
mainly where there was a specific
indication such as bypass surgery and
acute transfusion needs. Where there
was a marginal need for blood,
Hemopure was not indicated while the
clinical condition of the patient needed
careful evaluation before a blood
transfusion was considered.
‘Even where there’s an acute blood
loss situation and you need a rapid
blood volume expander, you do not
necessarily need cells or blood products
that carry oxygen as first-line therapy.
These are not volume expanders. The
clinician must evaluate whether the
patient needs the oxygen-carrying
products or volume replacement as first-
line therapy. There will always be
arguments for and against.’
Synthetic oxygen carriers have their
research origins in the United States
military in the 1950s and have obvious
applications anywhere that refrigeration
and blood are in short supply.
The SANBS cannot afford to remain
anything but hyper-vigilant. A recent
mortuary survey of young males
between 15 and 40 years who died of
trauma in KwaZulu Natal hospitals and
in the Johannesburg Hospital revealed
that 40 - 50% of them were HIV-positive,
said Boffard.
Chris Bateman
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The main reason for major reactions and deaths in patients from 2000 to 2003 – SANBS
KEY
• IBPT: incorrect blood product transfused 
• AHR: acute haemolytic reactions (including
anaphylaxis) 
• DHR: delayed haemolytic reactions
• TTD: transfusion-transmitted diseases (includes
viruses, bacteria and malaria)
• TA-GvHD: transfusion-associated graft-versus-host
disease.
• TRALI: transfusion-related acute lung injury
• PTP: post-transfusion purpura
• Other reactions: (e.g. incorrectly warmed and
transfusion of expired red cells)
